Immunomedics +18.5% AH on start of pancreatic cancer drug phase-3 trial

Immunomedics (IMMU) +18.5% AH after announcing it began treating patients with its 90Y-clivatuzumab tetraxetan pancreatic cancer drug in a late-stage clinical trial.

The phase-3 trial is a double-blind, randomized study aimed to evaluate the safety and efficacy of the drug combined with low-dose gemcitabine and best supportive care in patients with metastatic pancreatic cancer who have received at least two prior therapies.

From other sites
Comments (1)
  • nimmer
    , contributor
    Comments (4) | Send Message
    Thank you immu
    9 Jan 2014, 08:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs